Original reporting and analysis on the stories shaping biotech.
Telix Pharmaceuticals is spending up to $2.35 billion to acquire ITM Isotope Technologies Munich, one of the world's leading producers of the medical isotopes that power cancer-targeting radiopharmaceuticals. In a sector where supply chains are fragile and consolidation is accelerating, this might be the most important defensive move in oncology this year.
Prime Medicine just got the FDA's green light to test the most precise gene editor ever built inside a living human. PM-647 targets a single genetic "typo" that wrecks both the liver and lungs, and there's no approved fix for the liver side. The 2027 data readout could reshape the entire gene editing landscape.
BioNTech and OncoC4's gotistobart nearly doubled survival in previously treated squamous lung cancer patients compared to standard chemo. The catch? It's early-stage data, and the pivotal trial is still running.
Roche just inked a deal worth up to $1.53 billion for a trispecific antibody that hasn't even entered human trials yet. The drug grabs three targets at once, the partner is a Chinese biotech with a growing reputation, and the implications for both oncology and autoimmune disease are massive.
Mirum's brelovitug just hit its Phase 3 endpoint in hepatitis delta, a devastating liver disease that had exactly one approved treatment. With a novel mechanism and a possible 2027 FDA filing, the HDV market is about to get a lot more interesting.
The FDA just approved Eli Lilly's Onswik, a once-weekly insulin that eliminates more than 300 injections a year for people with type 2 diabetes. With Novo Nordisk's competing weekly insulin already on the market, the daily insulin era is officially on notice.
Adicet Bio's off-the-shelf CAR-T therapy, originally built for cancer, just produced durable lupus remissions in a Phase 1 trial. The results could validate the "immune reset" approach and upend decades of chronic immunosuppression.
AstraZeneca's gene-silencing drug Wainua just failed its biggest cardiac trial at ESC 2026, despite crushing it in nerve disease. The surprise flop reshapes the ATTR-CM competitive landscape and raises uncomfortable questions about whether "more suppression" actually means better outcomes.
The Trump administration just used a rare budget trick to claw back nearly $1 billion in approved spending, and the biotech world is watching nervously. The move didn't directly hit NIH, but it sets a dangerous precedent for an industry whose innovation pipeline starts with federal grants.
IASO Bio just showed that a single IV infusion can build cancer-killing CAR-T cells directly inside a patient's body, no factory required. If these early results hold up, the entire playbook for cell therapy could be about to change.
Eli Lilly just agreed to pay up to $3.35 billion for access to a Chinese biotech's discovery platform, and most people have never heard of the company. The deal signals just how aggressively Big Pharma is shopping in China for its next blockbuster.
Sarepta's Duchenne gene therapy Elevidys just received the FDA's most severe safety warning after pediatric patient deaths from liver failure. With 500 jobs cut and a failed confirmatory trial in the rearview, the company that once symbolized gene therapy's future is fighting to survive.
Lundbeck is uprooting its U.S. headquarters from suburban Chicago to Boston's Seaport, joining a growing wave of global pharma companies migrating to the biotech capital. The Danish neuroscience company says it's about talent and innovation, but the timing, the pipeline, and the real estate market tell a richer story.
Roche revealed the science behind RG-6182, a first-of-its-kind reversible MAGL inhibitor now in Phase II for progressive MS. In a disease with almost no approved options, this drug targets an enzyme nobody has successfully drugged before.
Eli Lilly just got FDA approval for a breast cancer combo that targets a specific gene mutation making tumors resistant to hormone therapy. It's a precision medicine win, a shot across AstraZeneca's bow, and a key piece of Lilly's plan to prove it's more than just the GLP-1 company.
For 40 years, scientists called the KRAS gene "undruggable." Revolution Medicines just proved them wrong with an FDA-approved pancreatic cancer therapy that roughly doubled survival. The era of RAS-targeted oncology has officially arrived.
Novo Nordisk just dropped $1.4 billion on a macrocycle startup days after another billion-dollar delivery deal. The injection giant is betting its future on pills, and the reason has everything to do with Eli Lilly.
Eli Lilly just agreed to pay up to $2.875 billion for a four-year-old biotech with one Phase 1 drug and zero revenue. The deal is the latest in Lilly's multi-billion-dollar immunology shopping spree, and it says a lot about where big pharma thinks the next blockbusters will come from.
A Shanghai biotech just got FDA clearance to test a drug that combines three "impossible" chemistry approaches in one molecule. NTS231 targets a cancer protein nobody's been able to drug, and the way it works is unlike anything in the clinic today.
A California jury hit Eli Lilly with a $90 million verdict for breaching an unwritten obligation in its partnership with Nektar Therapeutics. The case could change how every pharma collaboration deal gets negotiated from here on out.
A boy with Duchenne muscular dystrophy died in a Chinese CRISPR trial in 2025, and the world didn't find out until a year later. The delayed disclosure, ignored preclinical red flags, and persistent oversight gaps are raising urgent questions about whether China's gene-editing regulations are worth the paper they're written on.
The FDA just approved Mirum's Atebrioz for FOP, a nightmarish condition that turns your muscles and tendons into bone. The drug cut new bone formation by over 99% in trials, giving one of the world's smallest patient communities a powerful new option.
Join thousands of biotech professionals who start their day with our free, daily briefing.